Who owns Verrica Pharmaceuticals Inc. (VRCA)? Elite investor 13F holders
3 tracked elite investors reported holding Verrica Pharmaceuticals Inc as of 2026-06-30, including Caligan Partners, Cannell Capital, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
3 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Caligan Partners | VERRICA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 5654329.00 USD | 923910.000000 | Shares | hold | Original filing |
| Cannell Capital | VERRICA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-18 00:00:00 | 4797609.00 USD | 783923.000000 | Shares | add | Original filing |
| Renaissance Technologies LLC | VERRICA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 0.00 USD | 0.000000 | Shares | exited | Original filing |
| Renaissance Technologies LLC | VERRICA PHARMACEUTICALS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 133226.00 USD | 21769.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.